Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plant Extracts | 3 | 2018 | 112 | 0.440 |
Why?
|
| Rhodiola | 3 | 2018 | 16 | 0.350 |
Why?
|
| Phytotherapy | 2 | 2018 | 38 | 0.320 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 477 | 0.270 |
Why?
|
| Genes, APC | 1 | 2002 | 11 | 0.250 |
Why?
|
| Lactones | 1 | 2002 | 14 | 0.250 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 31 | 0.240 |
Why?
|
| Isoenzymes | 1 | 2002 | 127 | 0.240 |
Why?
|
| Cell Respiration | 2 | 2018 | 24 | 0.230 |
Why?
|
| Colorectal Neoplasms | 1 | 2002 | 196 | 0.210 |
Why?
|
| Leukopenia | 1 | 2019 | 15 | 0.210 |
Why?
|
| Emergencies | 1 | 2019 | 92 | 0.200 |
Why?
|
| Elective Surgical Procedures | 1 | 2019 | 105 | 0.190 |
Why?
|
| Neuroblastoma | 1 | 2018 | 81 | 0.170 |
Why?
|
| Mammary Glands, Human | 1 | 2017 | 50 | 0.170 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 101 | 0.160 |
Why?
|
| Genetic Therapy | 1 | 2002 | 565 | 0.160 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 960 | 0.160 |
Why?
|
| Prodrugs | 1 | 2016 | 27 | 0.160 |
Why?
|
| Phosphorylcholine | 1 | 2016 | 37 | 0.150 |
Why?
|
| Doxorubicin | 1 | 2016 | 78 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 110 | 0.150 |
Why?
|
| Melanoma, Experimental | 1 | 2015 | 40 | 0.150 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 54 | 0.140 |
Why?
|
| Epithelial Cells | 1 | 2017 | 330 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 2017 | 333 | 0.140 |
Why?
|
| Cell Line, Tumor | 5 | 2018 | 1180 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 544 | 0.140 |
Why?
|
| Glioblastoma | 1 | 2015 | 129 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2019 | 907 | 0.130 |
Why?
|
| Polymers | 1 | 2016 | 262 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 216 | 0.120 |
Why?
|
| Neoplasms | 1 | 2019 | 929 | 0.110 |
Why?
|
| GATA3 Transcription Factor | 1 | 2010 | 21 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2010 | 448 | 0.100 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2010 | 30 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 57 | 0.100 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2010 | 51 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 260 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2018 | 884 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 290 | 0.090 |
Why?
|
| Mice | 5 | 2016 | 8986 | 0.080 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2002 | 25 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2002 | 24 | 0.060 |
Why?
|
| Sulfones | 1 | 2002 | 35 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2002 | 59 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2016 | 496 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 309 | 0.060 |
Why?
|
| Animals | 5 | 2016 | 17868 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2010 | 152 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2019 | 60 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2010 | 2722 | 0.050 |
Why?
|
| Cytotoxins | 1 | 2018 | 11 | 0.050 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2018 | 20 | 0.050 |
Why?
|
| Humans | 7 | 2019 | 48363 | 0.050 |
Why?
|
| Survival Rate | 1 | 2019 | 659 | 0.040 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 16 | 0.040 |
Why?
|
| Female | 5 | 2019 | 26304 | 0.040 |
Why?
|
| Metabolomics | 1 | 2017 | 39 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 278 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 20 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 398 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 1122 | 0.040 |
Why?
|
| Cell Survival | 1 | 2018 | 520 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 996 | 0.040 |
Why?
|
| Plant Roots | 1 | 2015 | 48 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 484 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 181 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 1962 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 564 | 0.030 |
Why?
|
| Aged | 2 | 2019 | 10909 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 997 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 816 | 0.030 |
Why?
|
| Adult | 2 | 2019 | 13301 | 0.030 |
Why?
|
| Middle Aged | 2 | 2019 | 13617 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 410 | 0.030 |
Why?
|
| Male | 2 | 2019 | 23420 | 0.030 |
Why?
|
| Vimentin | 1 | 2010 | 17 | 0.030 |
Why?
|
| Risk Factors | 1 | 2019 | 4225 | 0.030 |
Why?
|
| Keratins | 1 | 2010 | 31 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 22 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 45 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 47 | 0.030 |
Why?
|
| Cadherins | 1 | 2010 | 64 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 3232 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 110 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 4317 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 217 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 201 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 119 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2010 | 99 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 193 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 317 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 898 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 3673 | 0.020 |
Why?
|
| United States | 1 | 2019 | 6149 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 3823 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 777 | 0.020 |
Why?
|